{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-039211","form_type":"8-K","ticker":"SCLX","cik":"0001820190","company_name":"Scilex Holding Co","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.064127+00:00","generated_at":"2026-05-26T02:25:44.975912+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Scilex licenses ZTlido and SP-103 to RoyaltyVest for ex-US markets; 50% net revenue share","bullets":["Licensed ZTlido (lidocaine topical system 1.8%) and SP-103 for commercialization outside US; Licensor retains US and stated territories.","RoyaltyVest pays Scilex Pharma 50% of net revenue from ex-US sales; annual $200K commitment until first regulatory approval.","Licensee must use commercially reasonable efforts to obtain regulatory approval in at least one Major Market Country within 18 months.","Scilex Pharma grants exclusive, non-transferable license; Scilex Holding Company provides parent guarantee for performance.","Agreement effective February 22, 2025, replacing the October 2024 Rest of World License Term Sheet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-039211","json":"https://secwatch.observer/filing/0001193125-25-039211.json","markdown":"https://secwatch.observer/filing/0001193125-25-039211.md","text":"https://secwatch.observer/filing/0001193125-25-039211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/0001193125-25-039211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/d859484d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:25:44.975912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}